Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: National Healthcare Properties, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2026
Event: Entry into a Material Agreement (Item 1.01)

Key Financial Metrics and Transaction Details

This filing reports a specific asset sale transaction rather than periodic financial performance metrics (e.g., revenue, net income, or cash flow for a fiscal period).

  • Asset Portfolio: 86 outpatient medical facilities.
  • Transaction Value: Approximately $528 million (before transaction expenses, property operating prorations, and other adjustments).
  • Debt Treatment: Approximately $278 million of secured debt to be defeased or assumed by the purchaser.
  • Counterparty: An affiliated third party.

Material Changes and Transaction Status

The Company entered into a definitive purchase and sale agreement (PSA) on May 4, 2026. This represents a material change in the Company's asset base pending closing.

  • Expected Closing: Third or fourth quarter of 2026.
  • Conditions Precedent: Completion of purchaser due diligence, lender approval for loan assumption, and other customary closing conditions.
  • Agreement Terms: Includes customary representations, warranties, covenants, and post-closing obligations.

Guidance, Outlook, and Risks

The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard closing conditions associated with the transaction.

Contingencies: The transaction is subject to customary closing conditions, including lender approval for the assumption of the $278 million secured debt.

Investor Verification Checklist

  • Verify the final closing date and whether the transaction closes in Q3 or Q4 2026.
  • Confirm the final net proceeds after transaction expenses and operating prorations.
  • Review the full text of the PSA (to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2026) for specific covenants and representations.
  • Monitor lender approvals regarding the assumption or defeasance of the $278 million secured debt.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.